Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Open accessThe DOI matches its Crossref record; 199 of the 202 references it cites were found in a registry or an index.
Abstract
Scientific advances over the last four decades have steadily infused the Alzheimer's disease (AD) field with great optimism that therapies targeting Aβ, amyloid, tau, and innate immune activation states in the brain would provide disease modification. Unfortunately, this optimistic scenario has not yet played out. Though a recent approval of the anti-Aβ aggregate binding antibody, Aduhelm (aducanumab), as a "disease-modifying therapy for AD" is viewed by some as a breakthrough, many remain unconvinced by the data underlying this approval. Collectively, we have not succeeded in changing AD from a largely untreatable, inevitable, and incurable disease to a treatable, preventable, and curable one. Here, I will review the major foci of the AD "disease-modifying" therapeutic pipeline and some of the "open questions" that remain in terms of these therapeutic approaches. I will conclude the review by discussing how we, as a field, might adjust our approach, learning from our past failures to ensure future success.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As previously anticipated, passive immunotherapy is considered the most effective approach to preventing and treating AD (see Figure 1) [36,37].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207 · cited 1×
“Generation of chimeric antigen receptor (CAR) T-cells targeting Aβ and testing of these in animal models of Aβ deposition might provide insight into the role that T-cells might play in active vaccination paradigms [35].”
BackgroundImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“These data reveal that antibodies that selectively bind to deposited Aβ, either because they bind aggregates with higher selectivity than monomer (Aduhelm [36], lecanemab [37], and gantenerumab [38, 39]) or bind modified forms of Aβ such as N3-pGAβ (donanemab[40–42]) highly enriched in deposited Aβ, can effectively lo…”
BackgroundThe blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 1×
“Overall Rationale Accumulation of tau as neurofibrillary tangles is a hallmark AD pathology [102].”
BackgroundYang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Tau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251 · cited 2×
“Tau PTMs are altered as tau accumulates in the brain and there is evidence that modifying the activity of proteins that control the PTM can alter the normal cellular function of tau and its subcellular distribution, but also alter its aggregation [108].”
BackgroundTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“A number of antibodies that have advanced to phase 3 studies in symptomatic AD have not shown evidence for efficacy either with respect to marked lowering of the PET ligand signal, or any significant clinical impact (ponezumab [44], solanezumab [39, 45–47], bapineuzumab [48], crenezumab [49]).”
BackgroundAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 1×
“Though previous studies have indicated that crosstalk between Aβ and tau pathologies can be modeled in transgenic mice [100, 101], there is still a huge gap in our understanding of what factors mediate that crosstalk.”
BackgroundFormation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 1×
“Though previous studies have indicated that crosstalk between Aβ and tau pathologies can be modeled in transgenic mice [100, 101], there is still a huge gap in our understanding of what factors mediate that crosstalk.”
BackgroundCherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 3×
“Additional studies on larger cohorts of AN-1792 vaccinated individuals also claim reductions in amount of amyloid deposited in some areas of the brain, relative to what might be expected [23, 25]; however, this data is again circumstantial.”
BackgroundResultNeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 5×
“These studies show possible hints of “amyloid plaque reduction” in postmortem tissue and possible functional benefit in responders [21, 23, 25, 26].”
BackgroundResultInfluentialA subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 1×
“Thus, selective targeting of these species using modulators of γ-secretase activity (GSMS) has also emerged as a possible way to target Aβ production and subsequently alter deposition [63, 64].”
BackgroundSelf-citationClinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207 · cited 1×
“Aβ aggregates can have a plethora of pathophysiologic functions [57, 58].”
BackgroundAlzheimer's disease: strategies for disease modification
Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,064 · cited 4×
“1 3 Aβ to attenuate amyloid deposition in the brains of amyloid depositing mice (reviewed in [12, 16, 17]).”
BackgroundInfluentialTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049
ARUK Consortium, Sims, R., GERAD/PERADES, C., van der Lee, S. J., Naj, A. C., Bellenguez, C., Badarinarayan, N., Jakobsdottir, J., Kunkle, B. W., Boland, A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3916 · Cited by 1,012 · cited 1×
“Genetic data that firmly links proteins that regulate microglial and other innate immune responses to AD risk has recently elevated the interest in novel developing immune modulators as disease-modifying agents [181, 182].”
BackgroundStructure-based classification of tauopathies
Shi, Y., Zhang, W., Yang, Y., Murzin, A. G., Falcon, B., Kotecha, A., van Beers, M., Tarutani, A., Kametani, F., Garringer, H. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03911-7 · Cited by 878 · cited 1×
“Given emerging data that different conformers of tau may predominate in different tauopathies [169, 170], we should be cognizant that the different tauopathies may be distinct disorders and success or failure of a therapeutic in one disease may not be predictive of its success or failure in another.”
BackgroundSperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847
Inflammasome signalling in brain function and neurodegenerative disease
Heneka, M. T., McManus, R. M., & Latz, E. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0055-7 · Cited by 836 · cited 1×
“Indeed, a CSF1R antagonist [183], TNFα antagonists [184, 185], an NLRPL3 antagonist [186, 187], a p38 MAPK inhibitor [188], Chromyln in combination with ibuprofen [189], lenadolidomide [190], and other approaches are being pursued conceptually as immune inhibitory strategies in AD.”
BackgroundThe secretases: enzymes with therapeutic potential in Alzheimer disease
De Strooper, B., Vassar, R., & Golde, T. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.218 · Cited by 799 · cited 4×
“Side effects appear to be mechanisms based and, in many cases, can be linked to inhibition of NOTCH1 cleavage and signaling [56, 63].”
BackgroundInfluentialSelf-citationThe A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J., Donohue, M., Salmon, D. P., & Aisen, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 760 · cited 1×
“Certainly, current prevention initiatives illustrate the power of these partnerships [90, 92, 199], but a more standardized regulatory path with appropriate financial models that is jointly developed with the many public and private stakeholders might ensure that these partnerships are lasting and not undermined by ch…”
BackgroundTREM2 — a key player in microglial biology and Alzheimer disease
Ulland, T. K., & Colonna, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0072-1 · Cited by 735 · cited 1×
“In contrast, GM-CSF (a CSFR1 activating ligand) [191, 192], TREM2 agonists (both small molecule and antibodybased approaches) [193], and a CD33/Siglec3 antagonists [194] (antibody) are being developed as immune activating approaches for AD.”
BackgroundA potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo
Yuzwa, S. A., Macauley, M. S., Heinonen, J. E., Shan, X., Dennis, R. J., He, Y., Whitworth, G. E., Stubbs, K. A., McEachern, E. J., Davies, G. J., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.96 · Cited by 717
Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s Disease
Wesseling, H., Mair, W., Kumar, M., Schlaffner, C. N., Tang, S., Beerepoot, P., Fatou, B., Guise, A. J., Cheng, L., Takeda, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.029 · Cited by 688 · cited 8×
“Pathologically associated tau is extensively post-translationally modified (PTM) with modifications including, but not limited to, extensive phosphorylation, acetylation, and O-glycosylation [106, 107].”
BackgroundInfluentialNecula, M., Kayed, R., Milton, S., & Glabe, C. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608207200 · Cited by 680
He, Z., Guo, J. L., McBride, J. D., Narasimhan, S., Kim, H., Changolkar, L., Zhang, B., Gathagan, R. J., Yue, C., Dengler, C., et al. (2018) · Nature Medicine · doi:10.1038/nm.4443 · Cited by 645 · cited 1×
“Seeded models including seeding of endogenous mouse tau have been developed and could be useful preclinic models, but, again, are quite artificial with respect to how they are generated [145].”
Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 637
Self-citationProtein transmission in neurodegenerative disease
Peng, C., Trojanowski, J. Q., & Lee, V. M.-Y. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0333-7 · Cited by 625 · cited 1×
“Preclinic studies demonstrate that prion-like seeding of tau pathology via this extracellular seed occurs in select model systems and can be mimicked by exogenous application of aggregated tau seeds [111, 112].”
BackgroundSalloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4161 · Cited by 619 · cited 1×
“Given that high-dose Aduhelm treatment results in a large increase in ARIA (41%) compared to placebo (10%), with ~ 1% of those treated with Aduhelm showing serious side effects, the high cost of the drug, and the intensive treatment regiment, it is clear that a larger clinical signal is needed to convince many stakeho…”
BackgroundIncreasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation
Yuzwa, S. A., Shan, X., Macauley, M. S., Clark, T., Skorobogatko, Y., Vosseller, K., & Vocadlo, D. J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.797 · Cited by 611
Thijssen, E. H., La Joie, R., Strom, A., Fonseca, C., Iaccarino, L., Wolf, A., Spina, S., Allen, I. E., Cobigo, Y., Heuer, H., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00214-3 · Cited by 607
Tau Kinetics in Neurons and the Human Central Nervous System
Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586 · cited 10×
“Pathologically associated tau is extensively post-translationally modified (PTM) with modifications including, but not limited to, extensive phosphorylation, acetylation, and O-glycosylation [106, 107].”
BackgroundInfluentialAnimal models of neurodegenerative diseases
Dawson, T. M., Golde, T. E., & Lagier-Tourenne, C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0236-8 · Cited by 576
Self-citationDempsey, C., Rubio Araiz, A., Bryson, K. J., Finucane, O., Larkin, C., Mills, E. L., Robertson, A. A. B., Cooper, M. A., O'Neill, L. A. J., & Lynch, M. A. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.12.014 · Cited by 571 · cited 1×
“Indeed, a CSF1R antagonist [183], TNFα antagonists [184, 185], an NLRPL3 antagonist [186, 187], a p38 MAPK inhibitor [188], Chromyln in combination with ibuprofen [189], lenadolidomide [190], and other approaches are being pursued conceptually as immune inhibitory strategies in AD.”
BackgroundCD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
Initiative, T. A. D. N., Bradshaw, E. M., Chibnik, L. B., Keenan, B. T., Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L. L., Imboywa, S., Lee, M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3435 · Cited by 570 · cited 1×
“In contrast, GM-CSF (a CSFR1 activating ligand) [191, 192], TREM2 agonists (both small molecule and antibodybased approaches) [193], and a CD33/Siglec3 antagonists [194] (antibody) are being developed as immune activating approaches for AD.”
BackgroundAlzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557
Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., & Koller, M. (2005) · Neurology · doi:10.1212/01.wnl.0000159743.08996.99 · Cited by 550 · cited 1×
“Clinical studies of AN-1792 were halted during phase 2 due to a 6% rate of aseptic meningoencephalitis with only an ~ 20% rate of “adequate” humoral responses to Aβ [19, 20].”
BackgroundAlzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Knopman, D. S., Jones, D. T., & Greicius, M. D. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12213 · Cited by 524
DeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516 · cited 1×
“Preclinical data supports tau ASOs as possible way to reduce tau aggregation and slow tau-induced neurodegeneration [168].”
BackgroundAmyloid-β oligomers: their production, toxicity and therapeutic inhibition
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Rowan, M. J., & Selkoe, D. J. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300552 · Cited by 507
Therapeutic strategies for Alzheimer's disease in clinical trials
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 452
Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy
Kondo, A., Shahpasand, K., Mannix, R., Qiu, J., Moncaster, J., Chen, C.-H., Yao, Y., Lin, Y.-M., Driver, J. A., Sun, Y., et al. (2015) · Nature · doi:10.1038/nature14658 · Cited by 445
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
Dujardin, S., Commins, C., Lathuiliere, A., Beerepoot, P., Fernandes, A. R., Kamath, T. V., De Los Santos, M. B., Klickstein, N., Corjuc, D. L., Corjuc, B. T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0938-9 · Cited by 438 · cited 9×
“Pathologically associated tau is extensively post-translationally modified (PTM) with modifications including, but not limited to, extensive phosphorylation, acetylation, and O-glycosylation [106, 107].”
BackgroundInfluentialKennedy, M. E., Stamford, A. W., Chen, X., Cox, K., Cumming, J. N., Dockendorf, M. F., Egan, M., Ereshefsky, L., Hodgson, R. A., Hyde, L. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9704 · Cited by 428
MAPT mutations, tauopathy, and mechanisms of neurodegeneration
Strang, K. H., Golde, T. E., & Giasson, B. I. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0197-x · Cited by 424 · cited 1×
“Do we understand tau pathobiology well enough to target tau successfully? More generally, the issue of how tau pathology is associated with neurodegeneration remains poorly understood [108, 146, 147].”
BackgroundSelf-citationAβ40 Inhibits Amyloid Deposition In Vivo
Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D. W., Golde, T., & McGowan, E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4849-06.2007 · Cited by 415
Self-citation“Lest we forget you — methylene blue …”
Schirmer, R. H., Adler, H., Pickhardt, M., & Mandelkow, E. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.12.012 · Cited by 414 · cited 1×
“Two of these trials are assessing methylene blue in different formulations and though methylene blue is touted as an aggregation inhibitor, it may have more complex effects on chaperone systems [166, 167].”
BackgroundAnti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
Golde, T. E., Schneider, L. S., & Koo, E. H. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.002 · Cited by 382
Self-citationPhase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
Salloway, S., Farlow, M., McDade, E., Clifford, D. B., Wang, G., Llibre-Guerra, J. J., Hitchcock, J. M., Mills, S. L., Santacruz, A. M., Aschenbrenner, A. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01369-8 · Cited by 359 · cited 1×
“These data reveal that antibodies that selectively bind to deposited Aβ, either because they bind aggregates with higher selectivity than monomer (Aduhelm [36], lecanemab [37], and gantenerumab [38, 39]) or bind modified forms of Aβ such as N3-pGAβ (donanemab[40–42]) highly enriched in deposited Aβ, can effectively lo…”
BackgroundBlood‐based biomarkers for Alzheimer's disease
Leuzy, A., Mattsson‐Carlgren, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114408 · Cited by 351
Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
Reiman, E. M., Langbaum, J. B. S., Fleisher, A. S., Caselli, R. J., Chen, K., Ayutyanont, N., Quiroz, Y. T., Kosik, K. S., Lopera, F., & Tariot, P. N. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-0059 · Cited by 339 · cited 1×
“Certainly, current prevention initiatives illustrate the power of these partnerships [90, 92, 199], but a more standardized regulatory path with appropriate financial models that is jointly developed with the many public and private stakeholders might ensure that these partnerships are lasting and not undermined by ch…”
BackgroundThe Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease
Brothers, H. M., Gosztyla, M. L., & Robinson, S. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00118 · Cited by 314 · cited 1×
“Though these data have renewed arguments about possible physiologic roles for Aβ [84], it is more likely that toxicity of both GSIs and β-secretase inhibitors is attributable to the net impact on signaling events mediated by the myriad of substrates each of the proteases cleave.”
BackgroundLongitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease
McDade, E., Wang, G., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Holtzman, D. M., Cairns, N. J., Goate, A. M., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006277 · Cited by 314 · cited 1×
“1 3 lates very well with amyloid deposition [51], it is clear that it is not a truly selective biomarker of cored plaque pathology, as areas of the brain with only diffuse amyloid can show marked amyloid PET ligand binding [52, 53].”
BackgroundOssenkoppele, R., Smith, R., Mattsson-Carlgren, N., Groot, C., Leuzy, A., Strandberg, O., Palmqvist, S., Olsson, T., Jögi, J., Stormrud, E., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1858 · Cited by 311 · cited 1×
“Tau PET ligand signals appear to track well with clinical progression, and it is certainly hoped that they can serve as an early predictive marker of efficacy [174, 175].”
BackgroundPropagation of Protein Aggregation in Neurodegenerative Diseases
Vaquer-Alicea, J., & Diamond, M. I. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045049 · Cited by 310 · cited 1×
“Preclinic studies demonstrate that prion-like seeding of tau pathology via this extracellular seed occurs in select model systems and can be mimicked by exogenous application of aggregated tau seeds [111, 112].”
BackgroundBoutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306
Novak, P., Schmidt, R., Kontsekova, E., Zilka, N., Kovacech, B., Skrabana, R., Vince-Kazmerova, Z., Katina, S., Fialova, L., Prcina, M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30331-3 · Cited by 304
Bateman, R. J., Benzinger, T. L., Berry, S., Clifford, D. B., Duggan, C., Fagan, A. M., Fanning, K., Farlow, M. R., Hassenstab, J., McDade, E. M., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.005 · Cited by 303 · cited 1×
“Certainly, current prevention initiatives illustrate the power of these partnerships [90, 92, 199], but a more standardized regulatory path with appropriate financial models that is jointly developed with the many public and private stakeholders might ensure that these partnerships are lasting and not undermined by ch…”
BackgroundEffects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease
Siemers, E. R., Quinn, J. F., Kaye, J., Farlow, M. R., Porsteinsson, A., Tariot, P., Zoulnouni, P., Galvin, J. E., Holtzman, D. M., Knopman, D. S., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000198762.41312.e1 · Cited by 295
γ-Secretase inhibitors and modulators
Golde, T. E., Koo, E. H., Felsenstein, K. M., Osborne, B. A., & Miele, L. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.005 · Cited by 272
Self-citationMcLaurin, J., Golomb, R., Jurewicz, A., Antel, J. P., & Fraser, P. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m906994199 · Cited by 266
Vellas, B., Black, R., Thal, L., Fox, N., Daniels, M., McLennan, G., Tompkins, C., Leibman, C., Pomfret, M., & Grundman, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602852 · Cited by 255 · cited 2×
“What caused the meningoencephalitis? The severe meningoencephalitis observed in some individuals in the phase 2 trial in many cases responded to steroid treatment suggesting that it was likely a T-cell mediated response, a finding consistent with post hoc postmortem studies and analysis of mRNA transcripts in the bloo…”
BackgroundResultKontsekova, E., Zilka, N., Kovacech, B., Novak, P., & Novak, M. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt278 · Cited by 248
Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial
Butchart, J., Brook, L., Hopkins, V., Teeling, J., Püntener, U., Culliford, D., Sharples, R., Sharif, S., McFarlane, B., Raybould, R., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001617 · Cited by 248
CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice
Mancuso, R., Fryatt, G., Cleal, M., Obst, J., Pipi, E., Monzón-Sandoval, J., Ribe, E., Winchester, L., Webber, C., Nevado, A., et al. (2019) · Brain · doi:10.1093/brain/awz241 · Cited by 235 · cited 1×
“Indeed, a CSF1R antagonist [183], TNFα antagonists [184, 185], an NLRPL3 antagonist [186, 187], a p38 MAPK inhibitor [188], Chromyln in combination with ibuprofen [189], lenadolidomide [190], and other approaches are being pursued conceptually as immune inhibitory strategies in AD.”
BackgroundStop Alzheimer’s before it starts
McDade, E., & Bateman, R. J. (2017) · Nature · doi:10.1038/547153a · Cited by 230
Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170560 · Cited by 219 · cited 1×
“Two of these trials are assessing methylene blue in different formulations and though methylene blue is touted as an aggregation inhibitor, it may have more complex effects on chaperone systems [166, 167].”
BackgroundReview: Modulating Factors in Amyloid-β Fibril Formation
McLaurin, J., Yang, D.-S., Yip, C. M., & Fraser, P. E. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4289 · Cited by 218
Genetics of Alzheimer’s disease: where we are, and where we are going
Bellenguez, C., Grenier-Boley, B., & Lambert, J.-C. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2019.11.024 · Cited by 215 · cited 1×
“Genetic data that firmly links proteins that regulate microglial and other innate immune responses to AD risk has recently elevated the interest in novel developing immune modulators as disease-modifying agents [181, 182].”
BackgroundKlein, G., Delmar, P., Voyle, N., Rehal, S., Hofmann, C., Abi-Saab, D., Andjelkovic, M., Ristic, S., Wang, G., Bateman, R., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0559-z · Cited by 212 · cited 1×
“These data reveal that antibodies that selectively bind to deposited Aβ, either because they bind aggregates with higher selectivity than monomer (Aduhelm [36], lecanemab [37], and gantenerumab [38, 39]) or bind modified forms of Aβ such as N3-pGAβ (donanemab[40–42]) highly enriched in deposited Aβ, can effectively lo…”
BackgroundNatural and synthetic saponin adjuvant QS-21 for vaccines against cancer
Ragupathi, G., Gardner, J. R., Livingston, P. O., & Gin, D. Y. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.18 · Cited by 206 · cited 1×
“Indeed, it has only recently been approved for human use as one of a multi-component adjuvant in a few vaccines [28, 29].”
BackgroundNicoll, J. A. R., Buckland, G. R., Harrison, C. H., Page, A., Harris, S., Love, S., Neal, J. W., Holmes, C., & Boche, D. (2019) · Brain · doi:10.1093/brain/awz142 · Cited by 202 · cited 3×
“Additional studies on larger cohorts of AN-1792 vaccinated individuals also claim reductions in amount of amyloid deposited in some areas of the brain, relative to what might be expected [23, 25]; however, this data is again circumstantial.”
BackgroundResultCytosolic Fc receptor TRIM21 inhibits seeded tau aggregation
McEwan, W. A., Falcon, B., Vaysburd, M., Clift, D., Oblak, A. L., Ghetti, B., Goedert, M., & James, L. C. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607215114 · Cited by 201 · cited 2×
“A third mechanism involves possible uptake of the tau seed and bound anti-tau antibody complex by neurons or other cells and then binding of this complex to the intracellular Fc binding TRIM21 protein [116, 117].”
BackgroundNeurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo
Kuchibhotla, K. V., Wegmann, S., Kopeikina, K. J., Hawkes, J., Rudinskiy, N., Andermann, M. L., Spires-Jones, T. L., Bacskai, B. J., & Hyman, B. T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318807111 · Cited by 193 · cited 1×
“Provocative studies demonstrate that tangle bearing neurons remain functional at least for some period of time [148].”
BackgroundBayoumy, S., Verberk, I. M. W., den Dulk, B., Hussainali, Z., Zwan, M., van der Flier, W. M., Ashton, N. J., Zetterberg, H., Blennow, K., Vanbrabant, J., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00939-9 · Cited by 190
Gordon, B. A., Blazey, T. M., Christensen, J., Dincer, A., Flores, S., Keefe, S., Chen, C., Su, Y., McDade, E. M., Wang, G., et al. (2019) · Brain · doi:10.1093/brain/awz019 · Cited by 180
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809316 · Cited by 177
Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody
Albert, M., Mairet-Coello, G., Danis, C., Lieger, S., Caillierez, R., Carrier, S., Skrobala, E., Landrieu, I., Michel, A., Schmitt, M., et al. (2019) · Brain · doi:10.1093/brain/awz100 · Cited by 177
Muhs, A., Hickman, D. T., Pihlgren, M., Chuard, N., Giriens, V., Meerschman, C., van der Auwera, I., van Leuven, F., Sugawara, M., Weingertner, M.-C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703137104 · Cited by 176
Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice
Gamache, J., Benzow, K., Forster, C., Kemper, L., Hlynialuk, C., Furrow, E., Ashe, K. H., & Koob, M. D. (2019) · Nature Communications · doi:10.1038/s41467-019-10428-1 · Cited by 176 · cited 1×
“Moreover, many widely used transgenic lines show variable phenotypes [143] and more recently tau-induced neurodegeneration in the commonly used Tg4510 line has been shown to be influenced by transgene insertion events [144].”
BackgroundThe Amyloid Phenomenon and Its Significance in Biology and Medicine
Dobson, C. M., Knowles, T. P. J., & Vendruscolo, M. (2020) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033878 · Cited by 173 · cited 1×
“Given the advances in the structural details of Aβ assemblies and mechanisms of nucleation and fibril elongation, it might be worth revisiting past efforts to try to drug Aβ aggregation [96, 97].”
BackgroundAlzheimer disease therapy: Can the amyloid cascade be halted?
Golde, T. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17527 · Cited by 164 · cited 2×
“Indeed, my colleagues and I have previously discussed in multiple reviews and perspectives the dilemma of targeting Aβ in the symptomatic phase of disease as opposed to prevention [10, 55, 57].”
BackgroundSelf-citationRevisiting FDA Approval of Aducanumab
Alexander, G. C., Knopman, D. S., Emerson, S. S., Ovbiagele, B., Kryscio, R. J., Perlmutter, J. S., & Kesselheim, A. S. (2021) · New England Journal of Medicine · doi:10.1056/nejmp2110468 · Cited by 162 · cited 4×
“Is the clinical efficacy in symptomatic disease sufficient to warrant use? Though Aduhelm has now been approved by the FDA, it is clear that many, if not most, in the field remain unconvinced of the clinical benefits of this antibody therapy [4, 5].”
BackgroundInfluentialThe case for low-level BACE1 inhibition for the prevention of Alzheimer disease
McDade, E., Voytyuk, I., Aisen, P. S. S., Bateman, R. J., Carrillo, M. C., Strooper, B. D., Haass, C., Reiman, E. M., Sperling, R. A., Tariot, P. N., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00545-1 · Cited by 162 · cited 2×
“Though a recent perspective suggests that there may be paths to revive clinical development β-secretase inhibitors, the authors acknowledge that more data is needed and that these efforts will be challenging [83].”
BackgroundDam, T., Boxer, A. L., Golbe, L. I., Höglinger, G. U., Morris, H. R., Litvan, I., Lang, A. E., Corvol, J., Aiba, I., Grundman, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01455-x · Cited by 160
MacPherson, K. P., Sompol, P., Kannarkat, G. T., Chang, J., Sniffen, L., Wildner, M. E., Norris, C. M., & Tansey, M. G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.02.010 · Cited by 158 · cited 1×
“Indeed, a CSF1R antagonist [183], TNFα antagonists [184, 185], an NLRPL3 antagonist [186, 187], a p38 MAPK inhibitor [188], Chromyln in combination with ibuprofen [189], lenadolidomide [190], and other approaches are being pursued conceptually as immune inhibitory strategies in AD.”
BackgroundSiemers, E. R., Dean, R. A., Friedrich, S., Ferguson-Sells, L., Gonzales, C., Farlow, M. R., & May, P. C. (2007) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31805b7660 · Cited by 156
Tau Kinetics in Neurons and the Human Central Nervous System
Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.04.035 · Cited by 154
Yuzwa, S. A., Shan, X., Jones, B. A., Zhao, G., Woodward, M. L., Li, X., Zhu, Y., McEachern, E. J., Silverman, M. A., Watson, N. V., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-42 · Cited by 152
UB‐311, a novel UBITh ® amyloid β peptide vaccine for mild Alzheimer's disease
Wang, C. Y., Wang, P., Chiu, M., Finstad, C. L., Lin, F., Lynn, S., Tai, Y., De Fang, X., Zhao, K., Hung, C., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.03.005 · Cited by 150
TRIM21—From Intracellular Immunity to Therapy
Foss, S., Bottermann, M., Jonsson, A., Sandlie, I., James, L. C., & Andersen, J. T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02049 · Cited by 149 · cited 2×
“A third mechanism involves possible uptake of the tau seed and bound anti-tau antibody complex by neurons or other cells and then binding of this complex to the intracellular Fc binding TRIM21 protein [116, 117].”
BackgroundAntolini, L., DiFrancesco, J. C., Zedde, M., Basso, G., Arighi, A., Shima, A., Cagnin, A., Caulo, M., Carare, R. O., Charidimou, A., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012778 · Cited by 149
Alzheimer's disease: The right drug, the right time
Golde, T. E., DeKosky, S. T., & Galasko, D. (2018) · Science · doi:10.1126/science.aau0437 · Cited by 147 · cited 3×
“Indeed, my colleagues and I have previously discussed in multiple reviews and perspectives the dilemma of targeting Aβ in the symptomatic phase of disease as opposed to prevention [10, 55, 57].”
BackgroundSelf-citationHöglinger, G. U., Litvan, I., Mendonca, N., Wang, D., Zheng, H., Rendenbach-Mueller, B., Lon, H.-K., Jin, Z., Fisseha, N., Budur, K., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30489-0 · Cited by 145
Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial
Mills, S. M., Mallmann, J., Santacruz, A. M., Fuqua, A., Carril, M., Aisen, P. S., Althage, M. C., Belyew, S., Benzinger, T. L., Brooks, W. S., et al. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.017 · Cited by 139
Alzheimer disease therapy: Can the amyloid cascade be halted?
Golde, T. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317527 · Cited by 139
Self-citationGong, C.-X., Liu, F., Grundke-Iqbal, I., & Iqbal, K. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9101 · Cited by 136 · cited 1×
“1 3 aggregates and is thought to compete for phosphorylation at those residues [153].”
BackgroundGraham, D. L., Gray, A. J., Joyce, J. A., Yu, D., O’Moore, J., Carlson, G. A., Shearman, M. S., Dellovade, T., & Hering, H. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.025 · Cited by 136
Roberts, M., Sevastou, I., Imaizumi, Y., Mistry, K., Talma, S., Dey, M., Gartlon, J., Ochiai, H., Zhou, Z., Akasofu, S., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0884-2 · Cited by 135
West, T., Hu, Y., Verghese, P. B., Bateman, R. J., Braunstein, J. B., Fogelman, I., Budur, K., Florian, H., Mendonca, N., & Holtzman, D. M. (2017) · PubMed · doi:10.14283/jpad.2017.36 · Cited by 132
Hey, J. A., Yu, J. Y., Versavel, M., Abushakra, S., Kocis, P., Power, A., Kaplan, P. L., Amedio, J., & Tolar, M. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0608-3 · Cited by 129 · cited 1×
“Nevertheless, several anti-Aβ aggregation agents remain in clinical development including ALZ-801 [72] and PRI-002 [73].”
BackgroundDhiman, K., Blennow, K., Zetterberg, H., Martins, R. N., & Gupta, V. B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03040-5 · Cited by 126 · cited 1×
“CSF fluid biomarkers of brain inflammation are also not well validated [196].”
BackgroundThinking laterally about neurodegenerative proteinopathies
Golde, T. E., Borchelt, D. R., Giasson, B. I., & Lewis, J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66029 · Cited by 124 · cited 1×
“Prion-like spread of tau in humans remains a hypothetical event [139].”
BackgroundSelf-citationThe Alzheimer’s disease drug development landscape
van Bokhoven, P., de Wilde, A., Vermunt, L., Leferink, P. S., Heetveld, S., Cummings, J., Scheltens, P., & Vijverberg, E. G. B. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00927-z · Cited by 123
Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease
Lowe, S. L., Willis, B. A., Hawdon, A., Natanegara, F., Chua, L., Foster, J., Shcherbinin, S., Ardayfio, P., & Sims, J. R. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12112 · Cited by 120
Safety and efficacy of sargramostim (GM‐CSF) in the treatment of Alzheimer's disease
Potter, H., Woodcock, J. H., Boyd, T. D., Coughlan, C. M., O'Shaughnessy, J. R., Borges, M. T., Thaker, A. A., Raj, B. A., Adamszuk, K., Scott, D., et al. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12158 · Cited by 119
Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies
Sigurdsson, E. M. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15202 · Cited by 116 · cited 1×
“Rationale The notion that antibody-based therapies could target tau pathology and tau-related neurodegeneration was quite controversial following publication of initial preclinical data [109, 110].”
BackgroundConcurrent alterations of O‐GlcNAcylation and phosphorylation of tau in mouse brains during fasting
Li, X., Lu, F., Wang, J., & Gong, C. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04735.x · Cited by 116
Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models
Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6463fje · Cited by 116
Self-citationDifferential Effects of an O-GlcNAcase Inhibitor on Tau Phosphorylation
Yu, Y., Zhang, L., Li, X., Run, X., Liang, Z., Li, Y., Liu, Y., Lee, M. H., Grundke-Iqbal, I., Iqbal, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035277 · Cited by 113
Takeda, S., Commins, C., DeVos, S. L., Nobuhara, C. K., Wegmann, S., Roe, A. D., Costantino, I., Fan, Z., Nicholls, S. B., Sherman, A. E., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24716 · Cited by 113 · cited 1×
“Further studies of human AD CSF show that species capable of seeding may be present, but are present at extremely low levels [140].”
BackgroundNovak, P., Zilka, N., Zilkova, M., Kovacech, B., Skrabana, R., Ondrus, M., Fialova, L., Kontsekova, E., Otto, M., & Novak, M. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.45 · Cited by 112
Lacosta, A.-M., Pascual-Lucas, M., Pesini, P., Casabona, D., Pérez-Grijalba, V., Marcos-Campos, I., Sarasa, L., Canudas, J., Badi, H., Monleón, I., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0340-8 · Cited by 111
Ayalon, G., Lee, S.-H., Adolfsson, O., Foo-Atkins, C., Atwal, J. K., Blendstrup, M., Booler, H., Bravo, J., Brendza, R., Brunstein, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2639 · Cited by 110
Microglial alterations in human Alzheimer's disease following Aβ42 immunization
Zotova, E., Holmes, C., Johnston, D., Neal, J. W., Nicoll, J. A. R., & Boche, D. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01156.x · Cited by 106
Organotypic brain slice cultures to model neurodegenerative proteinopathies
Croft, C. L., Futch, H. S., Moore, B. D., & Golde, T. E. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0346-0 · Cited by 106 · cited 1×
“Recent studies also highlight that fibrillar tau inclusions form rapidly and turnover with an appreciable half-life [149, 150].”
BackgroundSelf-citationInhibition of Amyloid-β Aggregation in Alzheimer's Disease
Wang, Q., Yu, X., Li, L., & Zheng, J. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990068 · Cited by 103
Amyloid duration is associated with preclinical cognitive decline and tau PET
Koscik, R. L., Betthauser, T. J., Jonaitis, E. M., Allison, S. L., Clark, L. R., Hermann, B. P., Cody, K. A., Engle, J. W., Barnhart, T. E., Stone, C. K., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12007 · Cited by 101 · cited 1×
“Perhaps with improvements in the power of biomarkers to predict future cognitive trajectories, it will be possible to assess efficacy of a potentially disease-modifying agent in the presymptomatic phase of disease in relatively small cohorts [197, 198].”
BackgroundDevelopment of a minimal saponin vaccine adjuvant based on QS-21
Fernández‐Tejada, A., Chea, E. K., George, C. M., Pillarsetty, N., Gardner, J. R., Livingston, P. O., Ragupathi, G., Lewis, J. S., Tan, D. S., & Gin, D. Y. (2014) · Nature Chemistry · doi:10.1038/nchem.1963 · Cited by 98 · cited 1×
“Indeed, it has only recently been approved for human use as one of a multi-component adjuvant in a few vaccines [28, 29].”
BackgroundThe Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?
Bhat, R. V., Andersson, U., Andersson, S., Knerr, L., Bauer, U., & Sundgren-Andersson, A. K. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179934 · Cited by 93 · cited 1×
“Previous efforts to target tau by inhibition of GSK3β have been largely discontinued [152] and most current efforts have focused on inhibition of O-GlcNAcase, the glycoside hydrolase enzyme that removes O-linked N-acetylglucosamine (N-GlcNAc) from proteins.”
BackgroundMolecular Genetics of Chromosome 17 Tauopathies
HUTTON, M. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06906.x · Cited by 92 · cited 1×
“Mutations in the gene (MAPT) encoding the tau protein that cause frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17 MAPT) demonstrate that alterations in tau are sufficient to cause neurodegeneration [103].”
BackgroundPredicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET
Schindler, S. E., Li, Y., Buckles, V. D., Gordon, B. A., Benzinger, T. L. S., Wang, G., Coble, D., Klunk, W. E., Fagan, A. M., Holtzman, D. M., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012775 · Cited by 91
Targeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89 · cited 1×
“It has been somewhat more challenging to identify tau therapeutics as opposed to Aβ-targeting therapies [105].”
BackgroundSelf-citationShort Aβ peptides attenuate Aβ42 toxicity in vivo
Moore, B. D., Martin, J., de Mena, L., Sanchez, J., Cruz, P. E., Ceballos-Diaz, C., Ladd, T. B., Ran, Y., Levites, Y., Kukar, T. L., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20170600 · Cited by 89
Self-citationTau-Focused Immunotherapy for Alzheimers Disease and Related Tauopathies
Sigurdsson, E. (2009) · Current Alzheimer Research · doi:10.2174/156720509789207930 · Cited by 87 · cited 1×
“Rationale The notion that antibody-based therapies could target tau pathology and tau-related neurodegeneration was quite controversial following publication of initial preclinical data [109, 110].”
BackgroundCognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease
Wessels, A. M., Lines, C., Stern, R. A., Kost, J., Voss, T., Mozley, L. H., Furtek, C., Mukai, Y., Aisen, P. S., Cummings, J. L., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12164 · Cited by 86
Open questions for Alzheimer’s disease immunotherapy
Golde, T. E. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt233 · Cited by 85 · cited 5×
“Overall, the studies conducted to date are consistent with a model whereby an anti-Aβ antibody must enter the brain and engage deposited Aβ [17].”
BackgroundResultInfluentialSelf-citationImbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies
Shelton, L. B., Koren, J., & Blair, L. J. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00724 · Cited by 84
Hickman, D. T., López-Deber, M. P., Ndao, D. M., Silva, A. B., Nand, D., Pihlgren, M., Giriens, V., Madani, R., St-Pierre, A., Karastaneva, H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.186338 · Cited by 83
An exploratory clinical study of p38 α kinase inhibition in Alzheimer's disease
Scheltens, P., Prins, N., Lammertsma, A., Yaqub, M., Gouw, A., Wink, A. M., Chu, H., van Berckel, B. N. M., & Alam, J. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.549 · Cited by 79 · cited 1×
“Indeed, a CSF1R antagonist [183], TNFα antagonists [184, 185], an NLRPL3 antagonist [186, 187], a p38 MAPK inhibitor [188], Chromyln in combination with ibuprofen [189], lenadolidomide [190], and other approaches are being pursued conceptually as immune inhibitory strategies in AD.”
BackgroundWang, X., Li, W., Marcus, J., Pearson, M., Song, L., Smith, K., Terracina, G., Lee, J., Hong, K.-L. K., Lu, S. X., et al. (2020) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.266122 · Cited by 79
Hori, Y., Takeda, S., Cho, H., Wegmann, S., Shoup, T. M., Takahashi, K., Irimia, D., Elmaleh, D. R., Hyman, B. T., & Hudry, E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.586602 · Cited by 78
Ross, J., Sharma, S., Winston, J., Nunez, M., Bottini, G., Franceschi, M., Scarpini, E., Frigerio, E., Fiorentini, F., Fernandez, M., et al. (2013) · Current Alzheimer Research · doi:10.2174/13892037113149990144 · Cited by 78
Andersson, C. R., Falsig, J., Stavenhagen, J. B., Christensen, S., Kartberg, F., Rosenqvist, N., Finsen, B., & Pedersen, J. T. (2019) · Scientific Reports · doi:10.1038/s41598-019-41105-4 · Cited by 76
Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
Rynearson, K. D., Ponnusamy, M., Prikhodko, O., Xie, Y., Zhang, C., Nguyen, P., Hug, B., Sawa, M., Becker, A., Spencer, B., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202560 · Cited by 76
Krishnamurthy, P. K., Deng, Y., & Sigurdsson, E. M. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00059 · Cited by 73
Immunotherapy for Alzheimer’s disease: past, present and future
Spencer, B., & Masliah, E. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00114 · Cited by 72 · cited 1×
“These preclinical studies showing reduction of amyloid by Aβ immunotherapies have now been reproduced in hundreds of independent preclinical studies (reviewed in [12, 13]).”
BackgroundKretner, B., Trambauer, J., Fukumori, A., Mielke, J., Kuhn, P., Kremmer, E., Giese, A., Lichtenthaler, S. F., Haass, C., Arzberger, T., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505952 · Cited by 72
Sur, C., Kost, J., Scott, D., Adamczuk, K., Fox, N. C., Cummings, J. L., Tariot, P. N., Aisen, P. S., Vellas, B., Voss, T., et al. (2020) · Brain · doi:10.1093/brain/awaa332 · Cited by 72
Ponezumab in mild‐to‐moderate Alzheimer's disease: Randomized phase II PET‐PIB study
Landen, J. W., Andreasen, N., Cronenberger, C. L., Schwartz, P. F., Börjesson‐Hanson, A., Östlund, H., Sattler, C. A., Binneman, B., & Bednar, M. M. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.003 · Cited by 69 · cited 1×
“A number of antibodies that have advanced to phase 3 studies in symptomatic AD have not shown evidence for efficacy either with respect to marked lowering of the PET ligand signal, or any significant clinical impact (ponezumab [44], solanezumab [39, 45–47], bapineuzumab [48], crenezumab [49]).”
BackgroundCharacterization of tau binding by gosuranemab
Sopko, R., Golonzhka, O., Arndt, J., Quan, C., Czerkowicz, J., Cameron, A., Smith, B., Murugesan, Y., Gibbons, G., Kim, S.-J., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105120 · Cited by 63
Abyadeh, M., Gupta, V., Gupta, V., Chitranshi, N., Wu, Y., Amirkhani, A., Meyfour, A., Sheriff, S., Shen, T., Dhiman, K., et al. (2021) · Aging and disease · doi:10.14336/ad.2021.0719 · Cited by 62
Chang, J. L., Hinrich, A. J., Roman, B., Norrbom, M., Rigo, F., Marr, R. A., Norstrom, E. M., & Hastings, M. L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.029 · Cited by 61
Towards PET imaging of the dynamic phenotypes of microglia
Beaino, W., Janssen, B., Vugts, D. J., de Vries, H. E., & Windhorst, A. D. (2021) · Clinical and Experimental Immunology · doi:10.1111/cei.13649 · Cited by 61 · cited 1×
“in the brain? Although PET ligands that assess microgliosis are utilized, the signal to noise ratio of these ligands based on binding to TSPO is relatively small especially in the elderly [195].”
BackgroundKutzsche, J., Jürgens, D., Willuweit, A., Adermann, K., Fuchs, C., Simons, S., Windisch, M., Hümpel, M., Rossberg, W., Wolzt, M., et al. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12001 · Cited by 58 · cited 1×
“Nevertheless, several anti-Aβ aggregation agents remain in clinical development including ALZ-801 [72] and PRI-002 [73].”
BackgroundAAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy
Ising, C., Gallardo, G., Leyns, C. E. G., Wong, C. H., Jiang, H., Stewart, F., Koscal, L. J., Roh, J., Robinson, G. O., Remolina Serrano, J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162125 · Cited by 57
Targeting tauopathy with engineered tau-degrading intrabodies
Gallardo, G., Wong, C. H., Ricardez, S. M., Mann, C. N., Lin, K. H., Leyns, C. E. G., Jiang, H., & Holtzman, D. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0340-6 · Cited by 57 · cited 1×
“Preclinical studies have shown that intracellular tau targeting recombinant antibody fragments delivered with recombinant adenoassociated viral vectors (intrabodies) can have modest impact on tau pathology and tau-induced neurodegenertive phenotypes in preclinical models [120, 142]; however, given the widespread distr…”
BackgroundMolecular mechanism of prion‐like tau‐induced neurodegeneration
Alonso, A. D., Beharry, C., Corbo, C. P., & Cohen, L. S. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.12.014 · Cited by 53
Targeting Post-translational Modifications on Tau as a Therapeutic Strategy for Alzheimer's Disease
Marcus, J. N., & Schachter, J. (2011) · Journal of Neurogenetics · doi:10.3109/01677063.2011.626471 · Cited by 50 · cited 1×
“regulate tau aggregation and toxicity in preclinical models [151].”
BackgroundImmunotherapy for Alzheimer’s disease
Morgan, D. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s348 · Cited by 50
BEYOND AMYLOID: The Next Generation of Alzheimer's Disease Therapeutics
Seabrook, G. R., Ray, W. J., Shearman, M., & Hutton, M. (2007) · Molecular Interventions · doi:10.1124/mi.7.5.8 · Cited by 48 · cited 1×
“Genetic and animal modeling data from the study of FTDP-17 MAPT only directly support tau as a therapeutic target in FTDP-17 MAPT; however, given the prominence of tau pathology in the AD brain, its correlation with clinical symptoms, and experimental evidence that Aβ can drive tau pathology in vivo, tau remains an at…”
BackgroundAn Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome
Belichenko, P. V., Madani, R., Rey-Bellet, L., Pihlgren, M., Becker, A., Plassard, A., Vuillermot, S., Giriens, V., Nosheny, R. L., Kleschevnikov, A. M., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152471 · Cited by 48
Yoshida, K., Moein, A., Bittner, T., Ostrowitzki, S., Lin, H., Honigberg, L., Jin, J. Y., & Quartino, A. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-0580-2 · Cited by 48 · cited 1×
“A number of antibodies that have advanced to phase 3 studies in symptomatic AD have not shown evidence for efficacy either with respect to marked lowering of the PET ligand signal, or any significant clinical impact (ponezumab [44], solanezumab [39, 45–47], bapineuzumab [48], crenezumab [49]).”
BackgroundMonitoring of Intracellular Tau Aggregation Regulated by OGA/OGT Inhibitors
Lim, S., Haque, M. M., Nam, G., Ryoo, N., Rhim, H., & Kim, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920212 · Cited by 47
Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders
Golde, T. E. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.027 · Cited by 45 · cited 4×
“Rationale Neuroinflammation has been a long-standing, but until more recently ill-defined, target for AD and many other neurodegenerative diseases [180].”
BackgroundInfluentialSelf-citationDeveloping a national strategy to prevent dementia: Leon Thal Symposium 2009
Khachaturian, Z. S., Barnes, D. E., Einstein, R., Johnson, S. C., Lee, V., Roses, A. D., Sager, M. A., Shankle, W. R., Snyder, P. J., Petersen, R. C., et al. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.01.008 · Cited by 44
Kinetics of human mutant tau prion formation in the brains of 2 transgenic mouse lines
Woerman, A. L., Patel, S., Kazmi, S. A., Oehler, A., Freyman, Y., Espiritu, L., Cotter, R., Castaneda, J. A., Olson, S. H., & Prusiner, S. B. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2822 · Cited by 44 · cited 1×
“Moreover, many widely used transgenic lines show variable phenotypes [143] and more recently tau-induced neurodegeneration in the commonly used Tg4510 line has been shown to be influenced by transgene insertion events [144].”
BackgroundGoodwin, M. S., Sinyavskaya, O., Burg, F., O’Neal, V., Ceballos-Diaz, C., Cruz, P. E., Lewis, J., Giasson, B. I., Davies, P., Golde, T. E., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.007 · Cited by 44
Self-citationDecourt, B., Wilson, J., Ritter, A., Dardis, C., DiFilippo, F., Zhuang, X., Cordes, D., Lee, G., Fulkerson, N., St Rose, T., et al. (2020) · Open Access Journal of Clinical Trials · doi:10.2147/oajct.s221914 · Cited by 43
Kaeser, S. A., Häsler, L. M., Lambert, M., Bergmann, C., Bottelbergs, A., Theunis, C., Mercken, M., & Jucker, M. (2022) · Acta Neuropathologica · doi:10.1007/s00401-021-02400-5 · Cited by 41 · cited 1×
“A recent study in mice shows that increases in extracellular tau appear to be a response to both Aβ amyloid and Danish familial dementia amyloid [179].”
BackgroundGhosh, U., Yau, W., Collinge, J., & Tycko, R. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111863118 · Cited by 40 · cited 1×
“Given the advances in the structural details of Aβ assemblies and mechanisms of nucleation and fibril elongation, it might be worth revisiting past efforts to try to drug Aβ aggregation [96, 97].”
BackgroundLo, A. C., Evans, C. D., Mancini, M., Wang, H., Shcherbinin, S., Lu, M., Natanegara, F., & Willis, B. A. (2021) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210296 · Cited by 39
Brain volume loss due to donanemab
Ayton, S. (2021) · European Journal of Neurology · doi:10.1111/ene.15007 · Cited by 38
Cryo-EM structures of τ filaments from human brain
Goedert, M. (2021) · Essays in Biochemistry · doi:10.1042/ebc20210025 · Cited by 35 · cited 1×
“Given emerging data that different conformers of tau may predominate in different tauopathies [169, 170], we should be cognizant that the different tauopathies may be distinct disorders and success or failure of a therapeutic in one disease may not be predictive of its success or failure in another.”
BackgroundGu, J., & Sigurdsson, E. M. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9576-5 · Cited by 34
Ratni, H., Alker, A., Bartels, B., Bissantz, C., Chen, W., Gerlach, I., Limberg, A., Lu, M., Neidhart, W. L., Pichereau, S., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00109 · Cited by 32
Therapeutic Strategies for Restoring Tau Homeostasis
Young, Z. T., Mok, S. A., & Gestwicki, J. E. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024612 · Cited by 31
A Purified Saponin Acts as an Adjuvant for a T-Independent Antigen
White, A. C., Cloutier, P. A., & Coughlin, R. T. (1991) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-6000-1_22 · Cited by 29 · cited 1×
“fractions of the bark of Chilean tree, Quillaja saponaria, and is an acylated 3, 28-bisdesmodic triterpene glycoside [27].”
BackgroundWang, G., Coble, D. W., McDade, E., Hassenstab, J. J., Fagan, A. M., Benzinger, T. L. S., Bateman, R. J., Morris, J. C., Xiong, C., & and the Dominantly Inherited Alzheimer Network (DIAN) (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.12.008 · Cited by 29
Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program
Roberts, C., Kaplow, J. M., Giroux, M., Krause, S., & Kanekiyo, M. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.4 · Cited by 28
Qiu, R., Ahn, J. E., Alexander, R., Brodney, M. A., He, P., Leurent, C., Mancuso, J., Margolin, R. A., Tankisheva, E., & Chen, D. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190228 · Cited by 27
Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions
Croft, C. L., Goodwin, M. S., Ryu, D. H., Lessard, C. B., Tejeda, G., Marrero, M., Vause, A. R., Paterno, G., Cruz, P. E., Lewis, J. M., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02264-9 · Cited by 27 · cited 1×
“Recent studies also highlight that fibrillar tau inclusions form rapidly and turnover with an appreciable half-life [149, 150].”
BackgroundSelf-citationDing, N., Ping, L., Shi, Y., Feng, L., Zheng, X., Song, Y., & Zhu, J. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.097 · Cited by 26
Boyd, H., & Booth‐Jones, M. (2012) · Brain Disorders & Therapy · doi:10.4172/bdt.1000101 · Cited by 25
Uro-Coste, E., Paiva, G. R. D., Guilbeau-Frugier, C., Sastre, N., Ousset, P. J., Silva, N. A. D., Lavialle-Guillotreau, V., Vellas, B., & Delisle, M.-B. (2010) · Clinical Neuropathology · doi:10.5414/npp29209 · Cited by 25
Bijttebier, S., Theunis, C., Jahouh, F., Martins, D. R., Verhemeldonck, M., Grauwen, K., Dillen, L., & Mercken, M. H. (2021) · Journal of Chromatography A · doi:10.1016/j.chroma.2021.462299 · Cited by 25
Tau Positron Emission Tomography in Autosomal Dominant Alzheimer Disease: Small Windows, Big Picture
McDade, E., & Bateman, R. J. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4026 · Cited by 22 · cited 1×
“1 3 lates very well with amyloid deposition [51], it is clear that it is not a truly selective biomarker of cored plaque pathology, as areas of the brain with only diffuse amyloid can show marked amyloid PET ligand binding [52, 53].”
BackgroundPeak, S. L., Gracia, L., Lora, G., & Jinwal, U. K. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.11.020 · Cited by 18
Neuropathology of progressive supranuclear palsy after treatment with tilavonemab
Koga, S., Dickson, D. W., & Wszołek, Z. K. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00283-0 · Cited by 18
AD molecular: Imaging tau aggregates with positron emissions tomography
Betthauser, T. J. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.007 · Cited by 15
Wey, S., Weng, C.-C., Lin, K., Yao, C.-H., Yen, T., Kung, H. F., Skovronsky, D., & Kung, M. (2009) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2009.01.013 · Cited by 13 · cited 1×
“1 3 lates very well with amyloid deposition [51], it is clear that it is not a truly selective biomarker of cored plaque pathology, as areas of the brain with only diffuse amyloid can show marked amyloid PET ligand binding [52, 53].”
BackgroundVitale, F., Ortolan, J., Volpe, B. T., Marambaud, P., Giliberto, L., & d’Abramo, C. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01003-7 · Cited by 10
Neuropathology of progressive supranuclear palsy after treatment with tilavonemab – Author's reply
Höglinger, G. U. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00284-2 · Cited by 7
A contentious FDA ruling for Alzheimer's disease
Neurology, T. L. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00215-5 · Cited by 7 · cited 1×
“Despite the recent Food and Drug Administration (FDA) approval of Aduhelm (aducanumab), hailed by some as the first disease-modifying therapy for AD, there remains a great unmet medical need [3].”
Background
Research works printed but not linked: 3
- 2021 Alzheimer’s disease facts and figures. Alzheimers Dement. 2021:17327–406. 33756057
- Black S Wilcock GK Hawworth J Hendrix S Zavitz K Christensen Db M-H Efficacy and safety ofMPC-7869 (R-flurbiprofen), a selective Abeta42 loering agent in mild Alzheimer’s disease: results of a 12-month phase 2 trial and 1-year follow on study Neurology 2006 66 Suppl2 A347
- Golde TE Petrucelli L Lewis J Targeting Aβ and tau in Alzheimer’s disease, an early interim report Exp Neurol 2010 223 2 252 266 10.1016/j.expneurol.2009.07.035 19716367 PMC2864363 · DOI · Paper page
Cited by
Decoding microglial immunometabolism: a new frontier in Alzheimer's disease research
Jung, E. S., Choi, H., & Mook-Jung, I. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00825-0 · Cited by 124
“Given this complexity, the efficacy of monotherapies, such as Aβ-targeting antibody treatments, remains limited, highlighting the growing need for combination therapy strategies [9–11].”
Kumar, V., Kim, S.-H., & Bishayee, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179540 · Cited by 124
Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94
“As previously anticipated, passive immunotherapy is considered the most effective approach to preventing and treating AD (see Figure 1) [36,37].”
BackgroundThe therapeutic landscape of tauopathies: challenges and prospects
Cummings, J. L., González, M. I., Pritchard, M. C., May, P. C., Toledo, L. M., & Harris, G. A. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01321-7 · Cited by 93
“These approaches have led to limited clinical success with two disease-modifying therapies recently approved [43, 56].”
BackgroundAlzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics
Manap, A. S. A., Almadodi, R., Sultana, S., Sebastian, M. G., Kavani, K. S., Lyenouq, V. E., & Shankar, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1429211 · Cited by 84
“Future clinical trials should not overlook the critical connection between amyloid, tau, and neuroinflammation to raise the likelihood of clinical efficacy (Golde, 2023).”
Metadata
- Authors
- Golde, T. E.
- Affiliations
- University of Florida (US)
- Corresponding author
- Golde, Todd E.
- ORCID
- Golde, Todd E.
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 19
- Issue
- 1
- Pages
- 209-227
- ISSN
- 1878-7479 (ISSN-L)
- PMC
- PMC8885119
- OpenAlex
- W4214774022
- Cited by
- 119
- References
- 202
- Citations by year
- 2026: 11 · 2025: 38 · 2024: 39 · 2023: 25 · 2022: 6
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 58 d)
- Locations
- Neurotherapeutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG066506)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, disease-modifying therapy, amyloid-beta, tau protein, innate immune activation, aducanumab, anti-amyloid antibodies, clinical trial failure, drug development strategy
- MeSH terms
- Alzheimer Disease, Brain, Humans, Immunotherapy, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.